overview
revers
reaction
use
gener
dcl
proteintempl
dcc
given
scheme
revers
reaction
take
place
water
make
biocompat
dcl
format
perform
presenc
adapt
absenc
preequilibr
protein
target
howev
revers
reaction
use
dcl
format
equilibr
fast
enough
allow
reequilibr
target
timescal
target
remain
stabl
condit
appli
also
match
criteria
requir
protein
certain
ph
temperatur
given
concentr
cosolv
order
speed
equilibr
catalyst
anilin
enzym
lipas
revers
acylhydrazon
ester
format
respect
might
ad
ensur
format
unbias
dcl
build
block
compar
reactiv
energi
furthermor
build
block
product
need
solubl
prevent
shift
equilibria
due
precipit
usual
cosolv
dimethyl
sulfoxid
dmso
use
maintain
product
build
block
solut
addit
import
reaction
chemoselect
avoid
cross
reactiv
function
group
build
block
protein
eg
lysin
residu
surfac
protein
given
reaction
dcl
revers
note
analyt
method
influenc
composit
librari
eg
trace
acid
liquid
chromatographi
lc
avoid
chang
equilibrium
composit
librari
first
frozen
presenc
target
protein
whereupon
analysi
take
place
method
choic
freez
dcl
depend
type
reaction
use
highli
revers
imin
exampl
reduc
correspond
amin
render
irrevers
acylhydrazon
easili
form
highli
revers
acid
condit
result
revers
reaction
slow
stop
use
increas
ph
reaction
catalyz
remov
deactiv
catalyst
convert
dcl
static
mixtur
case
care
design
control
experi
need
carri
ensur
unbias
result
case
reduct
step
use
freez
librari
studi
far
bind
pose
affin
affect
chemic
modif
aminebas
inhibitor
instanc
lot
flexibl
iminebas
parent
compound
invert
hydrogenbond
profil
besid
freez
librari
paramet
use
dcl
gener
affect
equilibrium
composit
amplif
factor
exampl
includ
choic
build
block
protein
concentr
concentr
type
cosolv
typic
dmso
temperatur
typic
room
temperatur
scheme
revers
reaction
use
proteintempl
dcc
identifi
bioactiv
compound
dynam
combinatori
chemistri
dcc
molecular
build
block
revers
form
via
coval
noncoval
bond
build
block
rel
larg
number
revers
product
gener
form
dynam
combinatori
librari
dcl
given
reaction
build
block
revers
member
dcl
continu
exchang
eventu
reach
thermodynam
equilibrium
extern
stimulu
protein
target
introduc
dynam
system
reequilibr
upon
select
noncoval
bind
librari
member
strongest
affin
target
specif
affin
librari
member
determin
number
type
strength
interact
favor
nonfavor
establish
protein
target
exampl
intermolecular
interact
van
der
waal
forc
ppstack
cationp
dipoledipol
hydrogenbond
iondipol
interact
well
ion
pair
ultim
best
binder
librari
amplifi
expens
librari
member
display
lower
affin
target
fig
identif
best
binder
circumv
need
synthesi
purif
character
everi
individu
librari
member
howev
date
remain
difficult
analyz
dcl
larg
size
prevent
dcc
becom
wide
use
tool
drug
develop
articl
analyt
method
use
proteintempl
dcc
describ
apart
gener
theori
exampl
recent
develop
report
briefli
discuss
figur
schemat
represent
proteintempl
dynam
combinatori
chemistri
analyt
techniqu
analysi
dcl
divid
chromatograph
spectroscop
techniqu
often
techniqu
combin
obtain
benefit
exampl
separ
complex
mixtur
lc
character
member
librari
use
mass
spectrometri
ms
prior
analysi
sampl
prepar
freez
equilibrium
enzym
remov
sampl
denatur
protein
achiev
heat
ad
organ
solvent
acetonitril
methanol
denatur
protein
subsequ
remov
filtrat
centrifug
case
ms
alway
necessari
remov
protein
direct
analysi
proteinligand
complex
possibl
overview
step
proteintempl
dcc
given
fig
nowaday
access
chromatograph
techniqu
highpressur
lc
hplc
standard
modern
chemistri
laboratori
owe
larg
varieti
column
avail
builtin
diod
array
detector
mixtur
compound
separ
character
subsequ
retent
time
uv
profil
hplc
chromatogram
analyz
compar
experi
perform
differ
condit
case
dcl
comparison
librari
presenc
absenc
target
protein
lead
identif
amplifi
andor
deplet
speci
dcc
first
appli
protein
target
group
lehn
use
imin
formationexchang
dcl
three
aromat
aldehyd
four
differ
amin
tenfold
excess
synthes
without
carbon
anhydras
ca
ii
model
enzym
mm
scheme
order
reduc
imin
amin
nabh
cn
mm
ad
reaction
mixtur
mixtur
incub
c
day
reaction
without
enzym
complet
within
h
analysi
dcl
thermal
denatur
enzym
min
c
ensur
releas
activ
site
possibl
tightli
bound
ligand
use
cellulos
membran
reaction
product
separ
ca
microcentrifug
filtrat
analysi
first
exampl
proteintempl
dcc
perform
comparison
hplc
trace
dcl
presenc
absenc
ca
shown
presenc
enzym
favor
format
condens
product
expect
display
strongest
affin
enzym
activ
site
strongest
binder
identifi
comparison
retent
time
separ
synthes
refer
compound
scheme
format
dynam
combinatori
librari
aldehyd
amin
presenc
carbon
anhydras
ca
result
imin
subsequ
irrevers
reduc
amin
recent
exampl
analysi
lc
report
greaney
cowork
demonstr
use
anilin
nucleophil
catalyst
revers
format
acylhydrazon
prior
report
acylhydrazon
chemistri
requir
acid
ph
compat
protein
target
besid
preequilibr
system
dcl
form
first
follow
freez
step
addit
protein
acylhydrazon
chemistri
consid
limit
use
proteintempl
dcc
introduct
anilin
nucleophil
catalyst
acylhydrazon
form
revers
ph
reach
steadyst
composit
h
instead
day
without
anilin
control
ph
equilibrium
dcl
easili
switch
proofofprincipl
studi
two
isozym
glutathion
stransferas
gst
use
play
import
role
cell
detoxif
emerg
target
treatment
drug
resist
chemotherapi
human
h
gst
tropic
diseas
schistosoma
japonicum
sj
gst
dcl
gener
aldehyd
relat
known
gst
substrat
cdnb
excess
ten
hydrazid
presenc
mm
anilin
ph
scheme
hydrazid
ad
larg
excess
respect
aldehyd
ensur
pseudofirstord
behavior
achiev
faster
equilibr
rate
dcl
contain
one
isozym
allow
stand
room
temperatur
occasion
shake
h
ph
adjust
freez
dcl
protein
remov
ultrafiltr
use
molecular
weight
cutoff
filter
da
subsequ
librari
analyz
hplc
compar
dcl
absenc
protein
dcl
show
clear
amplif
acylhydrazon
tbutylphenyl
thiophenyl
acylhydrazon
amplifi
presenc
hgst
sjgst
scheme
gener
acylhydrazonebas
dynam
combinatori
librari
aldehyd
hydrazid
b
structur
glutathion
gsh
gshconjug
aldehyd
c
acylhydrazon
amplifi
presenc
gst
isozym
schistosoma
japonicum
sj
gst
human
h
gst
respect
accur
ic
valu
resynthes
acylhydrazon
could
determin
due
poor
solubl
solv
problem
time
increas
potenc
acylhydrazon
glutathion
gsh
conjug
aldehyd
synthes
employ
dcl
hydrazid
scheme
highli
solubl
gsh
tripeptid
motif
expect
function
anchor
gshbind
site
enabl
explor
adjac
hydrophob
site
rang
hydrazid
fragment
hydrazid
fragment
select
enzym
best
binder
tbutylphenyl
thiophenyl
acylhydrazon
hgst
sjgst
respect
acylhydrazon
also
slightli
amplifi
dcl
hgst
signific
reduct
equilibrium
concentr
occur
f
sjgst
g
hgst
confirm
observ
amplif
caus
targetacceler
synthesi
sjgst
ad
preform
dcl
equilibrium
distribut
obtain
indic
amplif
result
genuin
thermodynam
select
fulli
explor
isozymespecif
amplif
two
dcl
ic
valu
separ
synthes
acylhydrazon
conjug
determin
amplifi
acylhydrazon
found
potent
biochem
assay
thiophenyl
acylhydrazon
display
lowest
ic
valu
sjgst
mm
tbutylphenyl
acylhydrazon
lowest
valu
among
four
conjug
g
h
hgst
mm
base
initi
studi
greaney
cowork
develop
stronger
bival
acylhydrazon
inhibitor
gst
isozym
bival
approach
repres
novel
concept
proteintempl
dcc
provid
access
much
divers
compound
onedimension
dcl
use
number
build
block
major
gst
exist
homodim
contain
conserv
gshbind
site
hydrophob
substratebind
site
dimer
interfac
inhibitor
featur
long
arm
either
end
central
scaffold
could
abl
span
dimer
interfac
address
gshbind
site
acylhydrazonebas
dcl
gener
compris
three
nitrosubstitut
benzaldehyd
deriv
known
binder
cdnb
four
bival
hydrazid
linker
presenc
anilin
nucleophil
catalyst
scheme
result
homoand
heterobisacylhydrazon
plu
addit
monoacylhydrazon
exclud
ez
isom
order
opportun
discrimin
hsite
differ
gst
homodim
linker
design
differ
length
lipophil
four
gst
isozym
murin
hgstp
sjgst
use
templat
revers
format
acylhydrazon
binder
incub
room
temperatur
h
hplc
analysi
adapt
dcl
use
two
hplc
column
seri
perform
compar
dcl
gener
absenc
protein
peak
identifi
deconvolut
combin
lcm
analysi
highest
amplif
obtain
sj
isozym
impress
amplif
hydrazon
scheme
scheme
anilinecatalyz
gener
acylhydrazonebas
dynam
combinatori
librari
aldehyd
bishydrazid
b
amplifi
gshconjug
homobisacylhydrazon
presenc
dcl
contain
show
strong
amplif
acylhydrazon
form
gshconjug
aldehyd
presenc
lead
signific
chang
hplc
trace
later
use
neg
control
studi
specif
bindingsit
interact
within
isoform
contrast
appear
interfer
dcl
equilibrium
certain
compound
exampl
bisacylhydrazon
contain
two
unit
degrad
monoacylhydrazon
enzym
therefor
use
templat
studi
rang
symmetr
bisacylhydrazon
contain
gshconjug
select
separ
synthes
order
assess
correspond
biochem
activ
scheme
tabl
ic
data
correl
well
amplif
observ
dcl
inhibitor
ic
nm
show
greatest
amplif
nearli
tenfold
potent
bisacylhydrazon
product
inhibit
data
sjgst
correl
less
well
amplif
observ
presum
due
competit
among
amplifi
librari
member
share
build
block
reduc
extent
amplif
due
lack
clear
equilibr
amplif
factor
observ
could
correl
ic
valu
elucid
role
linker
overlay
model
construct
base
crystal
structur
hgst
contain
ligand
model
show
linker
span
dimer
interfac
hgst
without
introduc
unfavor
interact
distort
dimer
structur
demonstr
dcc
bival
linker
particularli
suit
protein
target
challeng
address
structurebas
design
sbd
moment
lc
techniqu
hplc
wide
use
techniqu
lc
often
combin
ms
case
peak
immedi
assign
correspond
librari
member
otherwis
first
retent
time
uv
profil
confirm
use
separ
build
block
side
product
new
potenti
inhibitor
contain
strong
absorb
chromophor
overlook
uv
detect
use
evapor
light
scatter
detector
elsd
might
solv
problem
howev
use
elsd
requir
differ
equip
therefor
less
commonli
use
one
major
bottleneck
associ
hplc
lcm
limit
librari
size
although
analyt
method
possess
adequ
sensit
detect
subtl
chang
concentr
compound
interest
mixtur
mani
compound
often
fulli
resolv
limit
size
dcl
ten
compound
rather
thousand
possibl
ligand
futur
expect
method
use
ultra
perform
lc
uplc
increas
potenti
librari
size
even
size
limit
addit
downsid
hplc
analysi
requir
rel
larg
amount
protein
group
guo
report
novel
protocol
base
sizeexclus
chromatographi
sec
ms
direct
isol
identif
ligandtarget
adduct
dcl
proofofconcept
studi
hen
egg
white
lysozym
hewl
chosen
protein
target
import
contributor
immun
defens
attack
degrad
bacteri
cell
wall
hydrolysi
imin
format
select
revers
reaction
dcl
four
amin
ten
aldehyd
design
scheme
adapt
dcl
reduc
correspond
amin
use
nacnbh
incub
hewl
librari
mixtur
pass
sec
column
retain
nonbind
librari
potenti
binder
releas
denatur
elut
proteinligand
complex
use
acetonitril
eluent
analyz
electrospray
ioniz
esi
ms
three
member
dcl
found
bind
hewl
control
reaction
absenc
protein
compound
detect
ms
indic
sec
column
could
retain
unbound
librari
member
amin
inde
binder
hewl
case
librari
reduc
correspond
amin
imin
detect
sec
suggest
amin
rather
imin
intermedi
ligand
hewl
amin
synthes
mode
inhibit
rel
potenc
determin
evalu
effect
lysi
rate
micrococcu
lysodeikticu
amin
found
adopt
competit
mode
inhibit
bind
affin
follow
order
k
ae
mg
ml
k
ae
mg
ml
z
k
ae
mg
ml
build
first
report
guo
cowork
develop
secm
protocol
identif
competit
inhibitor
bovin
serum
albumin
bsa
serum
albumin
play
import
role
transport
deliveri
fatti
acid
metal
drug
bioactiv
small
molecul
abund
solubl
protein
constitu
circulatori
system
two
adapt
dcl
scheme
prepar
use
differ
catalyst
consist
carboxyl
acid
mm
alcohol
mm
carboxyl
acid
mm
alcohol
mm
sulfur
acid
immobil
lipas
candida
sp
ad
catalyst
respect
equilibr
day
aliquot
solut
appli
suitabl
sec
column
denatur
protein
addit
meoh
centrifug
supernat
analyz
esihrm
interestingli
librari
frozen
denatur
dcl
ethyl
palmit
identifi
new
binder
bsa
bind
affin
protein
ethyl
palmit
examin
via
fluoresc
spectroscopi
thermodynam
paramet
associ
constant
k
determin
use
va
nt
hoff
sternvolm
equat
respect
base
thermodynam
result
bind
process
spontan
dg
ethyl
palmit
consid
bound
bsa
mainli
hydrophob
interact
secm
protocol
circumv
need
resolut
librari
member
lc
one
major
bottleneck
prevent
use
significantli
larger
librari
size
drawback
sec
howev
fact
concentr
build
block
dcl
gener
limit
micromolar
even
nanomolar
rang
result
long
equilibr
time
caus
problem
protein
stabil
anoth
disadvantag
larg
amount
protein
use
eg
mg
hewl
mg
bsa
per
dcl
ensur
suffici
high
concentr
bind
inhibitor
proper
detect
ms
enzym
difficult
express
unstabl
time
secm
protocol
therefor
suitabl
yet
problem
could
possibl
address
selectedion
monitor
ms
case
select
mz
valu
detect
limit
librari
size
increas
analyt
time
significantli
nuclear
magnet
reson
nmr
spectroscopi
commonli
use
tool
organ
chemistri
laboratori
sinc
nondestruct
perform
directli
reaction
mixtur
extrem
sensit
make
invalu
tool
chemistri
sever
nmrbase
method
develop
use
proteintempl
dcc
includ
saturationtransf
differ
std
nmr
bnmr
waterligand
observ
via
gradient
spectroscopi
waterlogsi
competitionbas
hnmr
spectroscopi
stdnmr
spectroscopi
differ
normal
hnmr
spectrum
hnmr
spectrum
protein
select
satur
studi
fig
first
refer
spectrum
record
irradi
frequenc
set
valu
far
away
ligand
protein
signal
spectrum
also
known
offreson
spectrum
second
experi
spectrum
record
select
irradi
protein
without
influenc
ligand
usual
satur
step
perform
scheme
dynam
combinatori
librari
blue
box
red
box
secm
protocol
analysi
green
box
scheme
gener
dynam
combinatori
librari
amin
aldehyd
presenc
hen
egg
white
lysozym
hewl
follow
imin
reduct
nacnbh
separ
proteinbind
complex
sizeexclus
chromatographi
sec
ppm
region
characterist
aliphat
residu
protein
select
satur
transfer
aliphat
side
chain
whole
protein
via
spin
diffus
cross
relax
intramolecular
nuclear
overhaus
effect
fast
exchang
take
place
free
bound
ligand
allow
transfer
magnet
protein
receptor
ligand
proton
involv
bind
protein
surfac
satur
transfer
ligand
detect
chang
ligand
signal
satur
stdnmr
spectrum
upon
subtract
onreson
spectrum
offreson
spectrum
signal
observ
ligand
close
contact
protein
use
de
novo
sbd
combin
acylhydrazonebas
dcc
hstdnmr
spectroscopi
identifi
new
inhibitor
aspart
proteas
endothiapepsin
famili
aspart
proteas
involv
wide
rang
diseas
malaria
plasmepsin
alzheim
diseas
bsecretas
hypertens
renin
base
interact
observ
two
crystal
structur
endothiapepsin
without
water
molecul
activ
site
seri
acylhydrazon
design
retrosynthet
analysi
acylhydrazon
result
five
hydrazid
five
aldehyd
scheme
facilit
analysi
hstdnmr
spectroscopi
full
librari
divid
five
sublibrari
consist
one
aldehyd
five
hydrazid
addit
endothiapepsin
preform
sublibrari
acylhydrazon
identifi
analyz
iminetyp
acarbon
proton
signal
hstdnmr
spectra
five
sublibrari
featur
total
potenti
acylhydrazon
isom
includ
ez
isom
eight
binder
identifi
scheme
order
confirm
bind
mode
competit
potent
inhibitor
saquinavir
inhibit
constant
k
nm
ad
sublibrari
appear
saquinavir
signal
decreas
acylhydrazon
signal
hstdnmr
spectrum
confirm
specif
bind
acylhydrazon
subsequ
biochem
activ
eight
binder
determin
use
fluorescencebas
assay
seven
eight
acylhydrazon
inhibit
endothiapepsin
ic
valu
mm
scheme
confirm
outcom
hstdnmr
experi
one
acylhydrazon
insolubl
biochem
assay
condit
potent
inhibitor
display
ic
valu
mm
respect
order
determin
predict
bind
mode
endothiapepsin
crystal
soak
inhibitor
cocryst
structur
determin
confirm
silico
predict
either
direct
watermedi
interact
catalyt
dyad
achiev
hstdnmr
spectroscopi
benefit
nondestruct
directli
perform
use
sampl
furthermor
sinc
std
method
indic
hydrogen
atom
smallmolecul
inhibitor
close
proxim
protein
provid
inform
bind
mode
addit
competit
experi
known
binder
elucid
ligand
bind
pocket
known
ligand
assum
bind
mode
latter
known
stdnmr
spectroscopi
work
ligand
use
excess
therefor
requir
significantli
less
protein
lcm
howev
note
techniqu
discrimin
specif
nonspecif
binder
calcul
dissoci
constant
k
therefor
highli
overestim
addit
experi
ic
determin
requir
highaffin
binder
undergo
slow
chemic
exchang
nmr
timescal
observ
hstdnmr
appli
twice
analysi
dcl
first
group
analysi
bgalactosidas
inhibitor
base
hemithioacet
group
discuss
earlier
besid
hstdnmr
spectroscopi
nmr
method
develop
analysi
proteintempl
dcl
claridg
schofield
report
use
two
nmr
method
analyz
dcl
protein
templat
first
time
name
bnmr
spectroscopi
hwaterlogsi
use
nmr
techniqu
ternari
complex
enzym
boron
acid
sugar
dcl
monitor
identifi
binder
achymotrypsin
b
nucleu
quadrupolar
exploit
determin
hybrid
state
boron
atom
b
nucleu
sp
hybrid
trigon
planar
environ
exhibit
rel
broad
peak
compar
b
nucleu
highli
symmetr
sp
hybrid
tetrahedr
environ
give
much
sharper
peak
although
bnmr
spectroscopi
enabl
direct
observ
boronateenzym
complex
free
protein
background
signal
far
optim
analysi
dcl
bnmr
signal
broad
caus
boron
acid
similar
structur
overlap
addit
bnmr
spectroscopi
suffer
low
intrins
sensit
necessit
use
high
concentr
boron
acid
protein
compens
loss
signal
hwaterlogsi
featur
better
sensit
bnmr
spectroscopi
first
magnet
bulk
h
sampl
take
place
varieti
differ
transfer
mechan
small
molecul
interact
target
protein
detect
protein
concentr
low
hwaterlogsi
limit
exchang
kinet
revers
form
proteinligand
complex
might
still
suffer
overlap
signal
especi
larg
dcl
group
introduc
competitionbas
hnmr
method
screen
binder
human
depend
oxygenas
hypoxia
induc
factor
hif
hydroxylas
specif
prolyl
hydroxylas
domain
contain
enzym
isoform
factorinhibit
hif
fih
use
model
system
studi
natur
cosubstr
use
report
ligand
order
block
enzymecatalyz
turnov
avoid
oxid
diamagnet
fe
ii
nativ
fe
ii
substitut
paramagnet
catalyt
inact
zn
ii
competit
binder
displac
bound
bind
site
bulk
solut
unbound
observ
via
hnmr
spectroscopi
monitor
intens
report
signal
function
inhibitor
concentr
also
possibl
obtain
dissoci
constant
k
proofofprincipl
studi
boron
acid
scaffold
diol
hit
previou
studi
use
dynam
combinatori
ms
dcm
see
section
dynam
combinatori
ms
subject
competit
nmr
analysi
result
obtain
agreement
nondenatur
dcm
result
competitionbas
hnmr
techniqu
use
substoichiometr
amount
unlabel
protein
addit
advantag
ligandbas
nmr
techniqu
sitespecif
bind
inform
k
valu
ligand
high
low
affin
obtain
alreadi
briefli
introduc
section
liquid
chromatographi
ms
use
tool
dcc
sinc
compound
immedi
assign
mass
prior
analysi
complex
mixtur
separ
use
lc
also
direct
analysi
dcl
appli
two
main
ms
techniqu
appli
proteintempl
dcc
discuss
section
dynam
combinatori
ms
competit
ms
dcl
one
librari
member
known
bind
strongli
protein
serv
way
anchor
next
revers
reaction
take
place
support
ligand
obtain
favor
interact
bind
site
enzym
subsequ
nondenatur
esim
msm
use
direct
analysi
proteinligand
complex
recent
exampl
dcm
report
group
schofield
enabl
identif
new
inhibitor
base
acidsboron
ester
see
section
nmrbase
method
fe
ii
oxygenas
regul
human
hypox
respons
involv
treatment
anemia
ischemiarel
diseas
make
human
hydroxylas
import
drug
target
first
base
model
studi
support
ligand
design
particip
fe
ii
chelat
activ
site
boron
ester
exchang
scheme
predict
support
ligand
fit
well
side
pocket
activ
site
would
function
control
sinc
bind
activ
site
due
steric
clash
four
sublibrari
ten
diol
prepar
base
molecular
weight
ii
support
ligand
ad
dcl
ph
subsequ
eight
dcl
four
contain
four
contain
analyz
esim
order
determin
boron
ester
bind
preferenti
ii
possibl
boron
support
ligand
seven
boron
ester
deriv
seven
diol
found
bind
scheme
esim
analysi
mixtur
individu
diol
valid
dcm
result
absenc
individu
diol
eg
also
observ
bind
enzym
presum
chelat
fe
ii
employ
control
bind
boron
ester
found
bind
diol
enzym
observ
result
indic
mass
shift
observ
repres
boron
complex
instead
simultan
bind
diol
order
valid
dcm
result
ensur
result
obtain
bias
ms
techniqu
nmrbase
water
relax
experi
see
section
nmrbase
method
perform
confirm
dcm
method
ga
phase
agreement
nmr
studi
solut
verif
potenti
boron
acidboron
esterbas
dcm
method
perform
determin
bind
constant
stabl
analog
support
ligand
diol
scheme
tabl
analog
bind
significantli
stronger
boron
acid
gener
weaker
boron
ester
identifi
dcm
order
investig
bind
mode
boron
ester
stabl
analog
crystal
complex
contain
mn
ii
substitut
fe
ii
protein
cocryst
structur
reveal
bind
metal
bident
fashion
studi
effect
cell
activ
studi
perform
methyl
ester
deriv
scheme
compound
found
upregul
select
inhibit
phd
fih
overal
author
demonstr
inhibitor
base
boron
ester
could
discov
use
dcm
combin
nmr
spectroscopi
dcm
method
prevent
need
denatur
protein
chromatographi
separ
reaction
mixtur
freez
dcl
techniqu
fast
enabl
direct
analysi
proteinligand
complex
synthesi
individu
librari
member
valid
spectral
assign
requir
individu
build
block
could
directli
use
determin
bind
constant
despit
high
sensit
ms
howev
librari
compound
divid
sublibrari
ten
possibl
compound
schofield
cowork
also
describ
fragment
boron
acid
limit
dcm
approach
also
protein
use
nondenatur
ms
analysi
analysi
care
taken
sinc
noncoval
interact
might
translat
transit
solut
ga
phase
manner
lastli
due
soft
condit
use
dcm
method
straightforward
lot
time
effort
requir
establish
method
analyz
dcl
novel
protein
target
slightli
differ
approach
screen
dcl
competit
msbase
bind
assay
group
wanner
demonstr
effici
way
screen
hydrazon
inhibitor
use
pseudostat
librari
determin
bind
affin
competit
ms
bind
assay
gaminobutyr
acid
gaba
transport
chosen
target
import
subtyp
gaba
transport
decreas
gabaerg
neurotransmiss
assum
major
caus
neurolog
disord
like
epilepsi
parkinson
diseas
sleep
disord
inspir
work
andersen
et
al
hydrazon
deriv
design
resembl
inhibitor
scheme
nipecot
acid
deriv
use
hydrazin
build
block
aldehyd
divid
nine
equal
librari
four
possibl
hydrazon
per
dcl
order
get
rough
estim
equilibr
time
five
differ
aromat
aldehyd
mm
resembl
four
aldehyd
mm
react
separ
hydrazin
mm
absenc
target
reaction
monitor
uv
case
almost
complet
equilibrium
reach
within
h
therefor
h
incub
period
chosen
dcc
experi
presenc
target
adapt
dcc
ensur
nearli
full
convers
aldehyd
toward
product
hydrazin
mm
use
excess
respect
total
aldehyd
concentr
four
aldehyd
mm
case
equal
amount
structur
divers
aldehyd
ad
hydrazin
librari
obtain
constitu
tabl
bind
constant
k
ic
valu
stabl
analog
boron
acid
inhibitor
compound
r
x
k
mm
ic
deconvolut
experi
aldehyd
mm
strongest
bind
dcl
separ
test
presenc
hydrazin
mm
potent
inhibitor
identifi
hydrazon
decreas
marker
bind
less
tabl
hydrazon
decreas
marker
bind
therefor
consid
binder
medium
potenc
interestingli
five
potent
hydrazon
deriv
orthosubstitut
aldehyd
five
best
binder
synthes
correspond
bind
affin
pk
ic
valu
determin
use
ms
bind
assay
h
gaba
uptak
assay
respect
order
inhibitori
potenc
good
agreement
result
deconvolut
experi
tabl
one
year
later
wanner
cowork
report
followup
studi
start
one
potent
inhibitor
competit
msbase
bind
assay
employ
search
optim
highaffin
binder
dcl
form
hydrazin
total
differ
aldehyd
differ
substitu
place
biaryl
moieti
scheme
hydrazonecontain
librari
analyz
use
competit
ms
method
discuss
earlier
librari
led
reduc
marker
bind
deconvolut
hydrazon
show
higher
affin
potent
inhibitor
previou
studi
synthesi
hydrazon
higher
affin
compar
lead
compound
pk
ae
confirm
bind
assay
potent
hydrazon
display
pk
valu
ae
log
unit
higher
origin
lead
compound
scheme
order
develop
hydrazon
hit
lead
compound
carba
analog
five
structur
divers
hydrazon
deriv
synthes
inhibitori
effici
determin
pk
valu
carba
analog
roughli
log
unit
lower
correspond
hydrazon
rank
order
potenc
remain
mostli
unchang
carba
analog
potent
hydrazon
found
also
potent
inhibitor
carba
analog
pk
ae
studi
show
competit
msbase
bind
assay
pseudostat
hydrazon
librari
effici
hitidentif
strategi
ultim
use
start
point
develop
stabl
lead
compound
compar
bind
affin
initi
hydrazon
hit
use
nativ
marker
also
prevent
drawback
associ
radioisotop
provid
affin
marker
high
enough
low
protein
concentr
use
make
method
suitabl
protein
usual
obtain
extrem
low
concentr
membranebound
protein
like
g
proteincoupl
receptor
tabl
markerbind
data
pk
activ
pic
one
gener
problem
associ
analysi
proteintempl
dcl
need
larg
amount
protein
due
lack
sensit
analyt
method
also
suffer
difficult
timeconsum
expens
detect
activ
compound
group
rademann
report
dynam
ligat
screen
dl
revers
form
ligat
product
dcl
compet
dynam
equilibrium
fluorogen
report
substrat
target
enzym
use
enzymat
reaction
detect
fragment
small
amount
protein
requir
enabl
highthroughput
screen
ht
microtit
plate
demonstr
dl
method
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
pro
use
protein
target
cystein
proteas
essenti
replic
viru
insid
host
cell
respons
sar
first
fluorescencebas
assay
sarscov
pro
develop
use
substrat
actsasvlqamca
tabl
enzymat
cleavag
releas
fluorophor
acetamid
amca
next
peptid
aldehyd
inhibitor
mimic
nativ
proteas
substrat
act
direct
probe
synthes
oxazolidin
resin
given
aliphat
aldehyd
less
reactiv
toward
imin
format
aqueou
media
aromat
aldehyd
hypothes
imin
product
reaction
nucleophil
aliphat
peptid
aldehyd
could
form
stabil
protein
surfac
defin
activ
site
enabl
substrat
competit
well
microtit
plate
aldehyd
mix
enzym
eightfold
excess
one
chosen
nucleophil
select
contain
amin
thiol
hydrazin
substrat
ad
lead
releas
fluorophor
amca
measur
enzymat
turnov
monitor
fluoresc
spectroscopi
none
individu
nucleophil
show
inhibit
sarscov
pro
seven
nucleophil
librari
stronger
inhibit
aldehyd
alon
observ
tabl
confirm
bind
took
place
activ
site
proteas
exampl
alloster
site
deriv
activ
amin
studi
first
reduc
amin
product
tabl
test
hplc
bind
assay
show
k
valu
mm
compar
inhibitori
activ
truncat
amid
inact
peptid
acdsfdqoh
dsfdqoh
acdsfdqnh
support
direct
effect
aldehyd
bind
fragment
pocket
evid
provid
model
studi
inhibit
result
aldehyd
aldehyd
deriv
design
interact
activ
site
proteas
use
electrophil
end
dl
show
aldehyd
activ
inhibitor
proteas
thu
support
hypothesi
fragment
bind
specif
pocket
sarscov
pro
order
obtain
nonpeptid
inhibitor
target
protein
occupi
pocket
dl
appli
revert
mode
instead
use
aldehyd
bind
side
side
favor
employ
tabl
initi
veloc
v
substrat
convers
presenc
sarscov
pro
proteas
substrat
peptid
aldehyd
nucleophil
nucleophil
n
mm
min
second
screen
librari
amin
use
well
electrophil
incub
one
amin
proteas
fluorogen
substrat
three
activ
fragment
identifi
presenc
tabl
activ
fragment
use
reduct
amin
afford
amin
display
k
valu
mm
proofofconcept
studi
show
dl
method
effici
way
identifi
novel
inhibitor
k
valu
low
micromolar
rang
method
use
tini
reaction
volum
ml
per
well
requir
small
amount
protein
mm
sarscov
pro
per
well
work
effici
highthroughput
setup
schmuck
cowork
show
use
preequilibr
acylhydrazonebas
dcl
identif
btryptas
inhibitor
low
nanomolar
affin
preequilibr
approach
chosen
given
acylhydrazon
format
requir
acid
condit
toler
protein
target
btryptas
predomin
serin
proteas
human
mast
cell
respons
sever
allerg
inflammatori
disord
proteas
consist
four
ident
monom
stabil
heparin
featur
four
activ
site
central
access
pore
propos
pore
block
substrat
access
activ
site
therefor
dcl
design
base
revers
acylhydrazon
format
tetrapeptid
hydrazid
ditrialdehyd
case
twoand
threearm
peptid
acylhydrazon
larg
enough
partial
block
access
four
activ
site
amino
acid
arm
acylhydrazon
multipl
interact
protein
surfac
first
dcl
gener
five
diand
trialdehyd
five
peptidederiv
hydrazid
scheme
hydrazid
base
earlier
work
deriv
neg
charg
hydrazid
chosen
neg
control
sinc
neg
charg
would
unfavor
inhibit
btryptas
full
dcl
gener
mix
hydrazid
aldehyd
acet
buffer
ph
analyz
deconvolut
strategi
first
establish
lehn
cowork
analysi
ten
sublibrari
one
build
block
miss
gener
way
composit
sublibrari
compar
full
librari
case
build
block
miss
normal
part
activ
inhibitor
correspond
sublibrari
less
activ
full
librari
equimolar
concentr
build
block
use
librari
equilibr
room
temperatur
three
day
format
correspond
acylhydrazon
confirm
analyt
hplc
ms
assum
aldehyd
group
dcl
fulli
react
form
acylhydrazon
dcl
five
hydrazid
four
dialdehyd
one
trialdehyd
contain
total
possibl
constitu
ident
acylhydrazon
remov
diand
trialdehyd
symmetr
librari
size
reduc
differ
member
sublibrari
librari
size
chang
depend
number
function
group
featur
build
block
remov
could
confirm
compound
present
librari
rel
amount
therefor
possibl
inhibitor
identifi
best
possibl
inhibitor
limit
alway
appli
use
preequilibr
librari
scheme
gener
acylhydrazonebas
dynam
combinatori
librari
discov
new
potent
inhibitor
btryptas
b
diand
trialdehyd
build
block
c
tetrapeptid
hydrazid
gcp
guanidiniocarbonyl
pyrrol
format
preequilibr
librari
effect
btryptas
activ
determin
first
dcl
frozen
chang
ph
stop
revers
acylhydrazon
format
analysi
carri
highthroughput
enzymeact
assay
use
substrat
tocglyproargamc
gener
fluorophor
amc
upon
cleavag
enzym
enabl
monitor
rate
enzymat
hydrolysi
hydrazid
alon
show
activ
low
micromolar
rang
scheme
hydrazid
neg
control
aldehyd
found
weak
inhibitor
btryptas
ic
mm
respect
use
assay
activ
enzym
preequilibr
sublibrari
determin
compar
full
librari
build
block
concentr
mm
fig
inhibit
assay
show
hydrazid
requir
effici
enzym
inhibit
hydrazid
shown
activ
build
block
remov
enzym
activ
restor
compar
full
librari
hydrazid
similar
activ
less
activ
hydrazid
least
activ
approxim
recoveri
hydrazid
neg
control
show
neg
normal
activ
show
inhibitori
activ
increas
includ
dcl
expect
sinc
rel
concentr
activ
inhibitor
increas
regard
aldehyd
build
block
trialdehyd
emerg
activ
one
dialdehyd
show
much
smaller
inhibitori
effect
recoveri
remov
dcl
studi
role
aldehyd
second
librari
contain
five
aldehyd
activ
hydrazid
correspond
sublibrari
without
one
aldehyd
gener
fig
result
confirm
aldehyd
activ
build
block
hydrazid
remov
hydrazid
complet
restor
activ
enzym
confirm
aldehyd
alon
inhibit
btryptas
repres
acylhydrazon
synthes
order
determin
k
valu
tabl
individu
synthes
acylhydrazon
inhibitor
btryptas
k
valu
low
nanomolar
rang
three
order
magnitud
potent
individu
hydrazid
two
activ
inhibitor
display
k
valu
nm
respect
use
dixon
plot
verifi
compound
act
noncompetit
inhibitor
case
k
ic
valu
neg
control
show
inhibit
protein
interestingli
individu
hydrazid
slightli
differ
peptid
structur
show
similar
activ
tabl
acylhydrazon
show
differ
k
valu
differ
inhibit
profil
singl
mode
vs
biphas
behavior
differ
like
caus
differ
bind
mode
caus
chang
posit
guanidiniocarbonyl
pyrrol
group
molecularmechan
calcul
indic
inhibitor
bind
two
differ
type
bind
site
protein
surfac
inhibitor
block
pore
complet
partial
result
weaker
inhibit
enzym
addit
poreblock
abil
kj
mol
lower
energi
unbound
state
constitut
isom
presum
due
favor
stabil
intramolecular
interact
complex
btryptas
tabl
inhibitori
constant
k
individu
synthes
acylhydrazon
see
also
scheme
predict
kj
mol
stabl
complex
might
suggest
improv
inhibitori
activ
origin
combin
stronger
bind
protein
slightli
differ
bind
mode
less
stabl
groundstat
conform
inhibitor
group
report
combin
fragmentbas
drug
design
particular
fragment
grow
dcc
power
effici
strategi
convert
fragment
hit
dcl
contain
acylhydrazon
fluorescencebas
enzymat
assay
use
grow
fragment
potent
noncoval
inhibitor
aspart
proteas
endothiapepsin
start
point
fragment
chosen
base
favor
hbond
interact
amidin
group
catalyt
dyad
promis
physicochem
properti
fact
contain
heavi
atom
fragment
occupi
part
pocket
endothiapepsin
make
interact
catalyt
dyad
charg
hbond
interact
shown
one
previou
studi
acylhydrazon
moieti
suitabl
scaffold
address
catalyt
dyad
endothiapepsin
therefor
order
grow
pocket
acylhydrazon
linker
propos
base
molecularmodel
dock
studi
seri
nine
potenti
acylhydrazonebas
inhibitor
select
correspond
hydrazid
aldehyd
scheme
nine
dcl
contain
hydrazid
one
nine
aldehyd
gener
form
correspond
acylhydrazon
fluorescencebas
enzymat
assay
use
fluorogen
substrat
pno
glnargnh
hydrolysi
endothiapepsin
fluorogen
peptid
afford
fragment
lead
increas
fluoresc
scheme
allow
monitor
enzym
inhibit
fluoresc
spectroscopi
fig
analysi
reveal
two
dcl
display
consider
higher
inhibit
endothiapepsin
inhibit
mm
name
inhibit
ic
mm
inhibit
ic
mm
sinc
full
convers
correspond
acylhydrazon
ensur
hydrazid
use
excess
ic
valu
expect
lower
individu
synthes
isol
purifi
compound
therefor
identifi
acylhydrazon
hit
synthes
purifi
analysi
fluoresc
assay
ic
valu
ae
mm
mm
obtain
respect
overal
shown
combin
fragment
grow
dcc
power
techniqu
gener
novel
hit
aspart
proteas
endothiapepsin
fluorescencebas
assay
enabl
direct
screen
dcl
activ
inhibitor
shown
three
exampl
discuss
earlier
fluoresc
spectroscopi
power
method
proteintempl
dcl
analysi
use
enzymat
reaction
detect
inhibit
small
amount
protein
requir
given
fluorescencebas
assay
fast
enzym
need
assay
mixtur
short
time
make
type
analyt
method
ideal
preciou
unstabl
protein
possibl
ht
mean
larg
number
compound
screen
decreas
time
requir
analysi
congrev
et
al
astex
technolog
report
first
thu
far
exampl
direct
detect
ligand
dcl
use
xray
crystallographi
date
rcsb
protein
data
bank
report
protein
crystal
structur
elucid
xray
crystallographi
proofofconcept
studi
congrev
et
al
use
cyclindepend
kinas
target
due
involv
number
human
cancer
six
hydrazin
five
isatin
select
form
correspond
hydrazon
tabl
would
present
varieti
function
group
occupi
lipophil
pocket
atpbind
site
control
experi
lcm
confirm
possibl
product
form
dcl
individu
crystal
soak
reaction
solut
contain
monom
one
isatin
monom
case
except
one
result
electron
densiti
atp
pocket
indic
correspond
ligand
bound
synthesi
purif
ligand
activ
assay
show
ligand
bind
potent
enzym
inhibitor
ic
nm
bind
ligand
order
explor
potenti
xray
crystallographi
method
soak
experi
two
dcl
contain
crystal
led
observ
electron
densiti
latter
case
correspond
hydrazon
subsequ
complet
dcl
consist
hydrazin
isatin
analyz
presenc
electron
densiti
atpbind
pocket
confirm
potent
inhibitor
clearli
demonstr
xray
crystallographi
effici
power
method
direct
identif
binder
dcl
also
provid
detail
bind
mode
enzym
wellestablish
crystal
soak
protocol
destruct
xray
crystallographi
method
sever
advantag
previous
discuss
analyt
method
less
timeconsum
requir
larg
amount
protein
provid
bind
mode
ligand
identifi
despit
benefit
method
thu
far
use
analysi
dcl
probabl
due
fact
requir
specif
expertis
infrastructur
readili
avail
synthet
organ
chemistri
laboratori
tabl
gener
hydrazonebas
dynam
combinatori
librari
hydrazin
isatin
discov
new
inhibitor
cyclindepend
kinas
facilit
xray
crystallographi
modif
dcc
tether
strategi
exploit
identifi
weakli
bind
ligand
new
alloster
regulatori
site
fragment
disrupt
proteinprotein
interact
smallmolecul
stabil
conform
malleabl
protein
enabl
structur
character
ligand
bind
weakli
specif
target
site
protein
macromolecul
stabil
format
disulfid
bond
ligand
cystein
residu
protein
target
fig
cystein
natur
occur
one
select
instal
use
sitedirect
mutagenesi
compound
weak
affin
protein
disulfid
bond
entrop
stabil
equilibrium
shift
toward
modifi
protein
dcl
form
disulfid
ligand
protein
target
presenc
reduc
agent
bmercaptoethanol
reduc
condit
dcl
promot
rapid
thiol
exchang
equilibr
dcl
analyz
ms
long
potenti
binder
uniqu
molecular
weight
recent
fluorescencepolar
assay
use
detect
displac
peptid
ligand
protein
target
indirect
readout
disulfid
format
tether
first
report
well
cowork
model
system
anticanc
antiinfect
drug
target
thymidyl
synthas
ts
chosen
librari
contain
disulfidecontain
compound
ad
proteincontain
buffer
presenc
bmercaptoethanol
equilibr
analysi
perform
lcm
multipli
charg
ion
aris
protein
deconvolut
afford
mass
modifi
protein
screen
total
compound
highli
signific
structureact
relationship
observ
disulfidelink
ntosyldprolin
scheme
found
bind
strongli
ts
tosyl
group
found
bind
approxim
posit
orient
methylenetetrahydrofol
natur
cofactor
ts
therefor
glutam
residu
cofactor
graft
onto
methyl
group
ntosyldprolin
afford
modifi
ntosyldprolin
k
ae
mm
show
almost
higher
activ
ntosyldprolin
alon
k
ae
mm
introduct
ethylen
linker
increas
activ
even
obtain
k
valu
ae
nm
tether
also
use
substanti
increas
stabil
conform
dynam
protein
character
xray
crystallographi
wang
et
al
succeed
obtain
xray
crystal
structur
coactiv
gackix
domain
take
advantag
strategi
gackix
domain
coactiv
consist
amino
acid
known
interact
distinct
amphipath
sequenc
two
distinct
bind
site
activ
stimul
transcript
hundr
gene
includ
regul
hematopoiesi
memori
format
inflammatori
respons
flexibl
class
protein
make
character
crystallographi
imposs
either
complex
bind
partner
alon
mapp
cowork
appli
tether
strategi
screen
small
ligand
interact
gackix
domain
leucin
residu
rim
bind
surfac
mutat
cystein
afford
gackix
fragment
librari
scheme
optim
ligand
thymidyl
synthas
start
compound
select
coval
tether
use
disulfid
librari
figur
schemat
illustr
screen
use
tether
approach
cystein
residu
surfac
protein
form
disulfid
bond
differ
smallmolecul
fragment
compris
disulfid
screen
highthroughput
format
use
ms
assay
fragment
emerg
screen
high
tether
effici
gackix
scheme
character
bind
properti
ligand
selenomethionineincorpor
gackix
tether
crystal
structur
conform
dynam
protein
solv
xray
crystallographi
tabl
overview
analyt
method
use
proteintempl
dcc
discuss
articl
past
year
proteintempl
dcc
emerg
power
tool
enabl
identif
novel
ligand
biolog
target
allow
situ
synthesi
amplif
new
binder
protein
target
combin
effici
screen
method
proteintempl
dcc
hold
potenti
acceler
drugdiscoveri
process
significantli
nowaday
whole
rang
analyt
method
develop
hplc
lcm
sec
separ
differ
member
dcl
xray
spectroscopi
nmr
ms
character
binder
protein
target
tabl
major
bottleneck
dcc
howev
analysi
dcl
far
report
exampl
use
librari
small
moder
size
limit
address
order
allow
use
larger
complex
librari
transform
dcc
even
effici
wide
use
tool
medicin
chemistri
furthermor
expand
list
biocompat
revers
reaction
give
access
new
potenti
binder
structur
divers
also
facilit
develop
doubli
dynam
system
fragment
two
differ
pocket
activ
site
enzym
screen
simultan
type
system
compar
reactiv
certain
ph
requir
also
line
stabil
protein
target
